Infliximab in ulcerative colitis

Avi Levin, Oren Shibolet*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the effi cacy of infliximab in the treatment of moderate to severe UC.

Original languageEnglish
Pages (from-to)379-388
Number of pages10
JournalBiologics: Targets and Therapy
Volume2
Issue number3
StatePublished - 2008
Externally publishedYes

Keywords

  • Anti-TNF-α
  • Antibody
  • Crohn's disease
  • Infliximab
  • Ulcerative colitis

Fingerprint

Dive into the research topics of 'Infliximab in ulcerative colitis'. Together they form a unique fingerprint.

Cite this